Alzamend Neuro (ALZN) Research & Development (2020 - 2026)

Alzamend Neuro has disclosed Research & Development across 7 years of filings, most recently posting $434006.0 for Q2 2026.

• In Q2 2026, Research & Development fell 3.59% year-over-year to $434006.0; the TTM figure through Apr 2026 stood at $3.6 million (up 156.54% YoY), while the FY2026 annual figure was $3.6 million, up 156.53% from the prior year.
• Research & Development came in at $434006.0 for Q2 2026 at Alzamend Neuro, down from $1.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $2.9 million in Q1 2023 to a low of $176283.0 in Q4 2025.
• Average Research & Development over 5 years is $1.2 million, with a median of $1.3 million recorded in 2022.
• Year-over-year, Research & Development plunged 91.27% in 2024 and surged 742.75% in 2025.
• Over 5 years, Research & Development stood at $1.5 million in 2022, then jumped by 30.25% to $2.0 million in 2023, then sank by 84.42% to $311088.0 in 2024, then plunged by 43.33% to $176283.0 in 2025, then soared by 146.2% to $434006.0 in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $434006.0 in Q2 2026, $1.3 million in Q1 2026, and $176283.0 in Q4 2025.